作为治疗高度活跃的唯一同时服用抗发作药物,帕拉曼尼尔的有效性:来自现实世界多中心回顾性研究的见解
Angelo Pascarella1,2, Marilisa Pasquale1,2, Domenico Abelardo1,2
1Department of Medical and Surgical Sciences, Magna Græcia University of Catanzaro, Catanzaro, Italy.
Journal of neurology
|June 7, 2025
概括
珀兰 (PER) 有效地降低了高度活跃的患者的发作频率. 这项现实研究表明,PER是一种可容忍的附加疗法,可以改善难以治疗的发作病例的控制.
科学领域:
- 神经学 神经学
- 发病学 (Epileptology) 是一个专业的学科.
- 临床药理学 临床药理学
背景情况:
- 由于治疗耐药性,高度频繁的发作会给临床管理带来重大挑战.
- 评估perampanel (PER) 作为现实世界管理中的唯一附加疗法至关重要.
研究的目的:
- 评估PER作为高活性患者单独治疗的12个月疗效,安全性和耐受性.
- 根据基线发作频率和先前抗药物 (AED) 暴露,分析治疗结果.
主要方法:
- 作为唯一同时使用的抗发作药物 (PEROC) 的PERampanel研究数据的回顾性分析.
- 根据基线发作频率 (<5,5-20,>20次/月) 和之前的AED (≤1对>2) 分类的患者.
- 评估的保留率,响应率 (≥50%的发作减少),无发作率和不良事件 (AE).
主要成果:
- 在所有患者群体中,佩拉曼奈尔显著降低了发作频率.
- 12个月的保留率为75.1% (<5),68% (5-20),以及58.1% (>20次/月).
- 响应率分别为71.2%,61.8%和63.2%,无率分别为49.5% (<5),23.5% (5-20),15.8% (>20次/月).
- 常见的副作用包括30%的患者的头和易怒,没有显著的群体差异.
结论:
- 佩拉曼奈尔 (PER) 显示出良好的疗效和耐受性,作为在现实世界管理中唯一的补充疗法.
- 在高度活跃的患者中,PER是改善控制和改善生活质量的宝贵选择.
- 早期引入PER可能有利于具有挑战性的患者群体.
更多相关视频
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.0K
06:28Author Spotlight: Unraveling Seizure Dynamics and Novel Therapeutics for Status Epilepticus Using CMOS High-Density Microelectrode Array Systems
Published on: September 27, 2024
2.3K
相关概念视频
01:14Antiepileptic Drugs: Glutamate Antagonists
300
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
300
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
349
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
349
01:20Antiepileptic Drugs: Potassium Channel Activators
150
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
150
01:08Antiepileptic Drugs: Sodium Channel Blockers
459
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
459
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
273
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
273
01:17Antiepileptic Drugs: Calcium Channel Blockers
347
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
347